Centeon Humate-P
Executive Summary
Antihemophilic Factor VII/von Willebrand factor complex (human) approved April 1 "for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate." Humate-P is already marketed for treatment of hemophilia A